BACKGROUND: The tumor microenvironment is an emerging source of novel therapeutic targets in cancer. The glycosaminoglycan hyaluronan (HA) accumulates in 20-30% of tumors and is often associated with poor prognosis. MATERIALS AND METHODS: We developed a digitized, semiquantitative scoring system for tumor-associated HA content, then grouped tumors (from animal models or patients) according to the degree of HA accumulation (HA+1,2,3). The antitumor response to HA-depletion by pegylated PH20 hyaluronidase (PEGPH20) was then characterized as a function of HA accumulation. RESULTS: Semiquantitative grouping of tumors demonstrated that HA accumulation predicts the response of tumors in animal models to PEGPH20. Prospective analysis of HA content was used to predict response to PEGPH20 of squamous cell-type explants from patients with non-small cell lung cancer in nude mice. CONCLUSION: Measurement of HA is a viable biomarker approach for predicting antitumor response in animal models to the HA-depleting agent, PEGPH20.
BACKGROUND: The tumor microenvironment is an emerging source of novel therapeutic targets in cancer. The glycosaminoglycan hyaluronan (HA) accumulates in 20-30% of tumors and is often associated with poor prognosis. MATERIALS AND METHODS: We developed a digitized, semiquantitative scoring system for tumor-associated HA content, then grouped tumors (from animal models or patients) according to the degree of HA accumulation (HA+1,2,3). The antitumor response to HA-depletion by pegylated PH20 hyaluronidase (PEGPH20) was then characterized as a function of HA accumulation. RESULTS: Semiquantitative grouping of tumors demonstrated that HA accumulation predicts the response of tumors in animal models to PEGPH20. Prospective analysis of HA content was used to predict response to PEGPH20 of squamous cell-type explants from patients with non-small cell lung cancer in nude mice. CONCLUSION: Measurement of HA is a viable biomarker approach for predicting antitumor response in animal models to the HA-depleting agent, PEGPH20.
Authors: Sabah N Rezvani; Jinnan Chen; Jun Li; Ron Midura; Valbona Cali; John D Sandy; Anna Plaas; Vincent M Wang Journal: J Orthop Res Date: 2019-09-13 Impact factor: 3.494
Authors: Alex B Blair; Victoria M Kim; Stephen T Muth; May Tun Saung; Nathalie Lokker; Barbara Blouw; Todd D Armstrong; Elizabeth M Jaffee; Takahiro Tsujikawa; Lisa M Coussens; Jin He; Richard A Burkhart; Christopher L Wolfgang; Lei Zheng Journal: Clin Cancer Res Date: 2019-06-11 Impact factor: 12.531
Authors: Albrecht Neesse; Kristopher K Frese; Tashinga E Bapiro; Tomoaki Nakagawa; Mark D Sternlicht; Todd W Seeley; Christian Pilarsky; Duncan I Jodrell; Suzanne M Spong; David A Tuveson Journal: Proc Natl Acad Sci U S A Date: 2013-07-08 Impact factor: 11.205
Authors: Kit Man Wong; Kathryn J Horton; Andrew L Coveler; Sunil R Hingorani; William P Harris Journal: Curr Oncol Rep Date: 2017-07 Impact factor: 5.075
Authors: Clifford J Whatcott; Caroline H Diep; Ping Jiang; Aprill Watanabe; Janine LoBello; Chao Sima; Galen Hostetter; H Michael Shepard; Daniel D Von Hoff; Haiyong Han Journal: Clin Cancer Res Date: 2015-02-18 Impact factor: 12.531
Authors: Sunil R Hingorani; William P Harris; J Thaddeus Beck; Boris A Berdov; Stephanie A Wagner; Eduard M Pshevlotsky; Sergei A Tjulandin; Oleg A Gladkov; Randall F Holcombe; Ronald Korn; Natarajan Raghunand; Samuel Dychter; Ping Jiang; H Michael Shepard; Craig E Devoe Journal: Clin Cancer Res Date: 2016-01-26 Impact factor: 12.531
Authors: Li Kang; Louise Lantier; Arion Kennedy; Jeffrey S Bonner; Wesley H Mayes; Deanna P Bracy; Louis H Bookbinder; Alyssa H Hasty; Curtis B Thompson; David H Wasserman Journal: Diabetes Date: 2013-01-24 Impact factor: 9.461